| Literature DB >> 35979104 |
Tajana Pavić1, Stipe Pelajić2, Nina Blažević2, Dominik Kralj2, Milan Milošević3, Ivana Mikolasevic4, Ivan Lerotic2, Davor Hrabar2.
Abstract
BACKGROUND: Biliary obstruction is a relatively common condition that affects approximately 5 in 1000 people annually. Malnutrition is very common in patients with biliary obstruction and since it is associated with significant morbidity and mortality, it is important to identify factors and mechanisms involved in its development. AIM: To determine the influence of obstructive jaundice on the hormones controlling appetite and nutritive status.Entities:
Keywords: Biliary obstruction; Cholecystokinin; Ghrelin; Malnutrition
Year: 2022 PMID: 35979104 PMCID: PMC9258356 DOI: 10.12998/wjcc.v10.i17.5551
Source DB: PubMed Journal: World J Clin Cases ISSN: 2307-8960 Impact factor: 1.534
Figure 1Study enrollment flowchart.
Clinical characteristics of the participants
|
|
|
|
|
|
|
| Gender | Female | 12 (35%) | 9 (43%) | 13 (32%) | |
| Male | 22 (65%) | 12 (57%) | 27 (68%) | ||
| Age (yr) | Median (Q1-Q3) | 55.0 (43.0-67.0) | 66.0 (60.5-83.0) | 55.0 (43.0-67.0) | |
| Min-max | 33-84 | 55-88 | 39-90 | ||
| Biliary obstruction etiology | Biliary stones | 28 (82%) | |||
| Chronic pancreatitis | 5 (15%) | ||||
| Stenosing papillitis | 1 (3%) | ||||
| Tumor of pancreatic head | 15 (72%) | ||||
| Malignant lymphadenopathy | 4 (19%) | ||||
| Cholangiocarcinoma | 2 (9%) | ||||
| Duration of biliary obstruction (d) | 10.0 (5.0-20.2) | 14.0 (10.0-21.0) | NA | 0.045 | |
| Body weight (kg) | 80.5 (73.5-92.0) | 61.0 (46.0-75.8) | 72.5 (63.0-75.4) | 0.04 | |
| BMI (kg/m2) | 26.9 (23.7-28.7) | 21.8 (17.0-24.0) | 25.8 (22.9-27.9) | 0.001 | |
| Weight loss (%) | 3.8 (0.0-7.6) | 12.0 (8.1-18.0) | 0.0 (0.0-0.0) | 0.002 | |
| Body fat (%) | 24.0 (22.0-25.3) | 19.0 (13.0-24.0) | 29.5 (27.0-32.0) | < 0.001 | |
| NRS 2002 | 2.5 (0.0-3.3) | 4.0 (3.5-5.0) | 0.0 (0.0-0.0) | < 0.001 | |
| NRS 2002 | < 3 | 17 (50%) | 2 (9.5%) | 38 (95%) | < 0.001 |
| ≥ 3 | 17 (50%) | 19 (90.5%) | 2 (5%) | ||
| Appetite (VAS) | 4.0 (2.8-6.3) | 3.0 (2.0-6.0) | 4.0 (2.0-5.0) | 0.641 | |
| Pain (VAS) | 0.0 (0.0-1.3) | 1.0 (0.0-2.5) | 0.0 (0.0-0.0) | 0.001 | |
| Helicobacter pylori infection | 12 (35.2%) | 8 (38.1%) | 3 (7.5%) | 0.005 | |
| Smoking | 15 (44.1%) | 0 (0%) | 7 (17.5%) | < 0.001 |
Mann-Whitney U test (comparison between benign and malignant groups).
Kruskal-Wallis test (comparison between all three groups).
Values are presented as median (Q1-Q3) for continuous and as n (%) for categorical variables. BMI: Body mass index; NRS: Nutritional risk screening; VAS: Visual Analogue Scale; NA: Not available.
Etiology of biliary obstruction and various humoral parameters, median (25%-75%)
|
|
|
|
|
|
|
| CRP (mg/L) | 13.1 (6.6-19.6) | 6.3 (2.9-11.3) | 0.001 | 2.3 (0.9-3.4) | < 0.001 |
| ES (mm/h) | 25 (13.0-31.5) | 25 (12.0-41.0) | NS | 6.5 (4-13.2) | < 0.001 |
| Leukocytes (× 109) | 6.7 (4.9-8.9) | 6.7 (3.9-7.0) | NS | 5.9 (5.5-7.2) | NS |
| Hemoglobin (g/L) | 141 (123.8-147.0) | 125 (113.5-134.5) | 0.002 | 140 (135.0-156.5) | < 0.001 |
| Thrombocytes (× 109) | 220 (197.2-248.3) | 178 (113.5-289.5) | NS | 241 (188.5-289) | 0.042 |
| Bilirubin (mmol/L) | 85.3 (51.9-183.3) | 270 (145-359.8) | < 0.001 | 12.1 (10.7-14.0) | < 0.001 |
| AST (U/L) | 123 (84.0-212.3) | 155.0 (78.0-186.0) | NS | 19.0 (18.0-23.8) | < 0.001 |
| ALT (U/L) | 337.5 (84.8-547.5) | 232 (114-355.5) | NS | 16.0 (14.0-21.8) | < 0.001 |
| GGT (U/L) | 448 (333.8-602.8) | 396.0 (243.5-892.5) | NS | 18.0 (16.0-25.8) | < 0.001 |
| ALP (U/L) | 287.5 (261.8-418.5) | 281.0 (243.5-434.0) | NS | 83.5 (63.5-94.3) | < 0.001 |
| Blood glucose (mmol/L) | 5.8 (5.2-6.7) | 6.7 (6.3-7.6) | 0.006 | 5.3 (4.8-5.6) | < 0.001 |
| Creatinine (mmol/L) | 89.0 (82.0-110.5) | 105.0 (80.5-123.5) | NS | 84.5 (76.0-104.0) | 0.032 |
| Calcium (mmol/L) | 2.3 (2.2-2.5) | 2.4 (2.3-2.4) | NS | 2.4 (2.3-2.4) | NS |
| LDH (U/L) | 187.5 (152.8-213.5) | 196.0 (175.0-232.5) | NS | 158.0 (147.3-188.0) | 0.004 |
| Cholesterol (U/L) | 5.2 (4.9-6.8) | 5.4 (4.7-8.4) | NS | 6.0 (5.5-6.6) | 0.033 |
| Triglycerides (mmol/L) | 1.9 (1.1-2.3) | 2.4 (1.9-3.1) | 0.005 | 1.3 (1.1-1.6) | < 0.001 |
| Albumin (g/L) | 37.8 (32.9-41.0) | 36.0 (33.1-39.3) | NS | 43.0 (42.0-44.1) | < 0.001 |
| Ghrelin (pg/mL) | 1449.5 (1124.5-2398.8) | 1646.0 (1010.0-4179.0) | NS | 533.5 (368.5-931.5) | < 0.001 |
| CCK (pg/mL) | 291.7 (160.9-411.7) | 191.0 (142.6-218.5) | NS | 153.1 (72.3-262.4) | < 0.001 |
| IL-6 (pg/mL) | 7.0 (5.0-18.3) | 9.0 (80-11.0) | NS | 2.5 (2.0-4.0) | < 0.001 |
| TNF-α (pg/mL) | 11.0 (8.0-12.0) | 12.0 (10.5-14.5) | NS | 6.0 (5.0-7.0) | < 0.001 |
Mann-Whitney U test (comparison between benign and malignant groups).
Kruskal-Wallis test (comparison between all three groups).
Values are presented as median (Q1-Q3). AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; CRP: C-reactive protein; CCK: Cholecystokinin; ES: Erythrocyte sedimentation rate; GGT: Gamma-glutamyl transferase; LDH: Lactate dehydrogenase; NS: Not significant; IL-6: Interleukin 6; TNF-α: Tumor necrosis factor α.
Correlation of inflammatory markers and appetite regulating hormones with various nutritional parameters
|
|
|
|
|
|
| |
| Weight loss (%) | rho | -0.21 | 0.263 | 0.438 | 0.12 | 0.242 |
|
| 0.124 | 0.052 | 0.001 | 0.385 | 0.075 | |
| BMI (kg/m2) | rho | 0.638 | 0.31 | 0.024 | -0.342 | 0.411 |
|
| 0.001 | 0.021 | 0.861 | 0.011 | 0.002 | |
| NRS2002 | rho | -0.236 | 0.193 | 0.355 | -0.057 | 0.142 |
|
| 0.083 | 0.157 | 0.008 | 0.682 | 0.302 | |
| Adipose tissue (%) | rho | 0.313 | 0.136 | 0.069 | -0.348 | 0.289 |
|
| 0.02 | 0.324 | 0.617 | 0.009 | 0.033 | |
| Albumin (g/L) | rho | 0.002 | -0.384 | -0.461 | -0.024 | -0.026 |
|
| 0.987 | 0.004 | 0.001 | 0.861 | 0.848 | |
| Cholesterol (U/L) | rho | -0.162 | 0.054 | -0.212 | 0.209 | 0.355 |
|
| 0.238 | 0.696 | 0.121 | 0.125 | 0.008 | |
| Apetite (VAS) | rho | 0.047 | 0.039 | 0.037 | 0.027 | -0.121 |
|
| 0.733 | 0.776 | 0.786 | 0.847 | 0.379 | |
CRP: C-reactive protein; IL-6: Interleukin 6; TNF-α: Tumor necrosis factor α; CCK: Cholecystokinin; BMI: Body mass index; NRS: Nutritional risk screening; VAS: Visual analog scale.
Effects of biliary drainage
|
|
|
|
|
|
| Bilirubin (mmol/L) | 145 (63.9-230.7) | 88.5 (38.75-190.5) | 25 (18.85-38.7) | < 0.001 |
| ALT (U/L) | 133 (78-194) | 91.5 (63.75-144.25) | 30 (23-46.5) | < 0.001 |
| GGT (U/L) | 278 (103-421) | 194 (103.25-267.25) | 36 (28-64) | < 0.001 |
| ALP (U/L) | 448 (288.5-612.5) | 382.5 (184-606.5) | 85 (61-111) | < 0.001 |
| AST (U/L) | 284 (260.5-382) | 281.5 (231.75-429.25) | 123 (103.5-166) | < 0.001 |
| CRP (mg/L) | 10.0 (5.8-14.1) | 17.9 (5.9-26.8) | 8.3 (2.5-17.3) | 0.009 |
| IL-6 (pg/mL) | 9 (6-13) | 11 (7-22) | 9 (5-21.5) | 0.332 |
| TNF-α (pg/mL) | 11 (8.5-13) | 10 (9-12) | 10 (8-12.5) | 0.088 |
| Ghrelin (pg/mL) | 1549 (1079.5-2400.5) | 1648.5 (1137.25-2767) | 1612 (891.5-2962) | 0.552 |
| Cholecystokinin (pg/mL) | 213.0 (161.0-380.7) | 266.0 (203.0-400.5) | 235.0 (158.0-433.0) | 0.03 |
| Albumin (g/L) | 37.1 (33.0-40.8) | 35.0 (32.4 -38.0) | 38.0 (35.0-42.0) | < 0.001 |
| Appetite (VAS) | 4 (2-6) | 6 (4-8) | 7 (6-9) | < 0.001 |
| BMI (kg/m2) | 24.5 (21.3-28.2) | 24.4 (20.6-27.9) | 24.9 (21.2-26.8) | < 0.001 |
| Body fat (%) | 23 (17-25) | 23 (17-24) | 23 (19-25) | 0.002 |
| NRS 2002 | 3.0 (2.0-4.0) | 3.5 (2.0-4.0) | 0.0 (0.0-4.0) | < 0.001 |
Friedman test across three observations.
Values are presented as median (Q1-Q3); ALT: Alanine aminotransferase; GGT: Gamma-glutamyl transferase; ALP: Alkaline phosphatase; AST: Aspartate aminotransferase; CRP: C-reactive protein; IL-6: Interleukin 6; TNF-α: Tumor necrosis factor α; VAS: Visual analog scale; BMI: Body mass index; NRS: Nutritional risk screening.
Figure 2Appetite regulating hormone dynamics in biliary obstruction. A: Ghrelin levels during and after resolution of biliary obstruction compared to those of the control group; B: Cholecystokinin levels during and after resolution of biliary obstruction compared to those of the control group. CCK: Cholecystokinin.
Figure 3Differences in inflammatory marker changes depending on nutritional risk. A: Interleukin 6 levels during and after biliary obstruction depending on nutritional status; B: Tumor necrosis factor α levels during and after biliary obstruction depending on nutritional status. TNF-α: Tumor necrosis factor α; NRS: Nutritional risk screening.